Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults [PDF]
Vaccines, 2022 Mumps outbreaks and breakthrough infections of measles and rubella have raised concerns about waning of vaccine-induced immunity after two doses of measles-mumps-rubella (MMR) vaccination.
Patricia Kaaijk +7 more
doaj +4 more sources
Measles-Mumps-Rubella Vaccine and COVID-19 Relationship. [PDF]
mBio, 2020 I have read the article by Fidel and Noverr with great interest (1). As told in the article, could measles-mumps-rubella (MMR) vaccine really be a “low-risk–high-reward” measure in COVID-19? However, I have several concerns about their opinion/hypothesis posed in their article (1).
Özdemir Ö.
europepmc +3 more sources
Comparative long-term follow-up study of persistence of immunity after JVC-001 measles, mumps, and rubella vaccination in Japanese children [PDF]
Human Vaccines & ImmunotherapeuticsJVC-001 is a novel measles-mumps-rubella (MMR) combined vaccine. In the J301 clinical trial, healthy 1-y-old Japanese children received either JVC-001 or marketed measles-rubella (MR) and mumps vaccines as control group.
Tetsuo Nakayama +5 more
doaj +2 more sources
Determination of ELISA reactive mumps IgG antibodies in MMR vaccine recipients in comparison with MMR vaccine naive children: A cross sectional study [PDF]
Scripta Medica, 2021 Background/Aim: Mumps is by vaccine preventable infectious disease characterised by parotitis. In India mumps vaccines are not currently used under National Immunisation Programme (NIP).
Gupta Riya, Saxena Naveen, Gupta Parul
doaj +1 more source
Эпидемиология и вакцинопрофилактика, 2021 Relevanc. Measles, mumps and rubella, despite many years of vaccination, retain their epidemiological and social significance at the present time. The aim of the work is to study the safety and immunogenicity. Of the vaccine for the prevention of measles,
I. V. Feldblium +9 more
doaj +1 more source
A Review on Rubella Vaccine: Iran (1975-2019) [PDF]
Archives of Razi Institute, 2021 The first Attenuated rubella vaccine was developed by Parkman and Meyer in 1966. Ten years later in the 1975s, the rubella vaccine was developed in Razi Vaccine and serum research institute) RVSRI).
A Shafayi, A Mohammadi
doaj +1 more source
Quality analysis of a combined domestic vaccine for the prevention of measles, rubella and mumps
Вопросы вирусологии, 2022 Introduction. The need to maintain a high level of vaccination coverage against measles, rubella and mumps in conditions of an increased risk of outbreaks of infections due to violations of vaccination tactics associated with the pandemic of coronavirus ...
Anna S. Binyatova +5 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2022 Measles is a vaccine-preventable viral disease whose vaccination coverage remains low in Zambia, where the target group for vaccination is children aged 9 to 18 months.
Kalonde Malama +11 more
doaj +1 more source
Post Vaccine Rubella During a Measles Outbreak: Clinical Case
Acta Médica Portuguesa, 2021 Rubella is a vaccine preventable infection, and congenital rubella the most feared complication of this disease. Although young adult women are at greatest risk of post-vaccine rubella, this is also the group who potentially benefits the most from ...
Luísa Graça +3 more
doaj +1 more source
HEALTHCARE WORKERS IN BULGARIA - ARE THEY PROTECTED FROM VACCINE-PREVENTABLE INFECTIONS?
Problems of Infectious and Parasitic Diseases, 2023 Background: Healthcare workers (HCWs) are at increased risk of exposure to many viral infections, including vaccine preventable diseases (VPDs) such as measles, mumps and rubella (MMR) as compared to non-HCWs.
Radostina Stefanova +4 more
doaj +1 more source